|Table of Contents|

Analysis on the clinical features of 54 patients with PD-1 inhibitor associated thyrotoxicosis

Journal Of Modern Oncology[ISSN:1672-4992/CN:61-1415/R]

Issue:
2023 23
Page:
4340-4343
Research Field:
Publishing date:

Info

Title:
Analysis on the clinical features of 54 patients with PD-1 inhibitor associated thyrotoxicosis
Author(s):
WANG Xiaoyan1; 2; YU Haiying3; YANG Ying4
1.School of Medicine,Wuhan University of Science and Technology,Hubei Wuhan 430081,China;2.Department of Endocrinology;3.Department of Oncology;4.Department of Geriatrics,Xiangyang Central Hospital(Affiliated Hospital of Hubei University of Arts and Science),Hubei Xiangyang 441000,China.
Keywords:
immune checkpoint inhibitor; PD-1 inhibitor; thyrotoxicosis; thyroiditis
PACS:
R730.6
DOI:
10.3969/j.issn.1672-4992.2023.23.008
Abstract:
Objective:To analyze the clinical features of programmed death-1(PD-1) inhibitors in the treatment of tumor-induced thyrotoxicosis to guide clinical diagnosis and treatment.Methods:A retrospective study was conducted in patients with thyrotoxicosis after receiving PD-1 inhibitors in Xiangyang Central Hospital from January 2019 to January 2022,and the initiation,duration,clinical manifestations,time when thyroid function returned to normal or hypothyroidism,and T3/T4 ratio were analyzed.Results:Of the 610 oncology patients treated with PD-1 inhibitors,54 cases of patients with thyrotoxicosis were included in the study.The median time to thyrotoxicosis is 44 days,and clinically,most patients do not have typical thyroid-specific symptoms.The median duration of thyrotoxicosis was 43 days.The median T3/T4 ratio during thyrotoxicosis was 13.8(range 7.8 to 19.7) ng/μg.Conclusion:Thyrotoxicosis caused by PD-1 inhibitors is not uncommon,mostly painless thyroiditis,atypical clinical symptoms,easy to misdiagnose and miss,thyroid ECT and T3/T4 ratio less than 20 ng/μg is meaningful for distinguishing hyperthyroidism and thyroiditis.

References:

［1］中华医学会内分泌学分会免疫内分泌学组.免疫检查点抑制剂引起的内分泌系统免疫相关不良反应专家共识(2020)［J］.中华内分泌代谢杂志,2021，37(1):1-16. Immunoendocrinology Group,Society of Endocrinology,Chinese Medical Association.Chinese expert consensus on the immune checkpoint inhibitors-induced endocrine immune-related adverse events(2020)［J］.Chinese Journal of Endocrinology and Metabolism,2021，37(1):1-16.
［2］BARROSO-SOUSAR，BARRY WT,GARRIDO-CASTRO AC,et al.Incidence of endocrine dysfunction following the use of different immune checkpoint inhibitor regimens:A systematic review and Meta-analysis［J］.JAMA Oncology,2018,4(2):173-182.
［3］RUGGERI RM,CAMPENNI A,GIUFFRIDA G,et al.Endocrine and metabolic adverse effects of immune checkpoint inhibitors:An overview(what endocrinologists should know)［J］.Journal of Endocrinological Investigation,2019,42(7):745-756.
［4］MARTINS F,SOFIYA L,SYKIOTIS GP,et al.Adverse effects of immune-checkpoint inhibitors:Epidemiology,management and surveillance［J］.Nature Reviews Clinical Oncology,2019,16(9):563-580.
［5］李洪敏,赵永才,郭鹏,等.免疫检查点抑制剂相关甲状腺毒性研究进展［J］.现代肿瘤医学,2023,31(8):1568-1572. LI HM,ZHAO YC,GUO P,et al.Research progress of thyroid toxicity related to immune checkpoint inhibitors［J］.Modern Oncology,2023,31(8):1568-1572.
［6］MUIR CA,CLIFTON-BLIGH RJ,LONG GV,et al.Thyroid immune-related adverse events following immune checkpoint inhibitor treatment［J］.Journal of Clinical Endocrinology and Metabolism,2021,106(9):e3704-e3713.
［7］IYER PC,CABANILLAS ME,WAGUESPACK SG,et al.Immune-related thyroiditis with immune checkpoint inhibitors［J］.Thyroid:Official Journal of the American Thyroid Association,2018,28(10):1243-1251.
［8］DELIVANIS DA,GUSTAFSON MP,BORNSCHLEGL S,et al.Pembrolizumab-induced thyroiditis:Comprehensive clinical review and insights into underlying involved mechanisms［J］.Journal of Clinical Endocrinology and Metabolism,2017,102(8):2770-2780.
［9］KOBAYASHI T,IWAMA S,YASUDA Y,et al.Patients with antithyroid antibodies are prone to develop destructive thyroiditis by nivolumab:A prospective study［J］.Journal of the Endocrine Society,2018,2(3):241-251.
［10］LEE H,HODI FS,GIOBBIE-HURDER A,et al.Characterization of thyroid disorders in patients receiving immune checkpoint inhibition therapy［J］.Cancer Immunology Research,2017,5(12):1133-1140.
［11］VILLA NM,FARAHMAND A,DU L,et al.Endocrinopathies with use of cancer immunotherapies［J］.Clinical Endocrinology,2018,88(2):327-332.
［12］OKADA N,IWAMA S,OKUJI T,et al.Anti-thyroid antibodies and thyroid echo pattern at baseline as risk factors for thyroid dysfunction induced by anti-programmed cell death-1 antibodies:A prospective study［J］.British Journal of Cancer,2020,122(6):771-777.
［13］BRANCATELLA A,VIOLA N,BROGIONI S,et al.Graves' disease induced by immune checkpoint inhibitors:A case report and review of the literature［J］.European Thyroid Journal,2019,8(4):192-195.
［14］NARKAR RR,MISHRA L,BALIARSINHA AK,et al.Rapid differential diagnosis of thyrotoxicosis using T3/T4 ratio,FT3/FT4 ratio and color doppler of thyroid gland［J］.Indian Journal of Endocrinology and Metabolism,2021,25(3):193-197.
［15］CHEN X,ZHOU Y,ZHOU M,et al.Diagnostic values of free triiodothyronine and free thyroxine and the ratio of free triiodothyronine to free thyroxine in thyrotoxicosis［J］.International Journal of Endocrinology,2018,2018:4836736.
［16］BARAL S,SHRESTHA PK,PANT V.Serum free T(3) to free T(4) ratio as a useful indicator for differentiating destruction induced thyrotoxicosis from Graves' disease［J］.Journal of Clinical and Diagnostic Research,2017,11(7):Oc12-Oc14.

Memo

Memo:
-
Last Update: 2023-10-31